文献速递瓣膜外科

极手术高危患者中重度二尖瓣或三尖瓣反流患者行经导管主动脉瓣置换术

Transcatheter aortic valve replacement in patients with severe mitral or tricuspid regurgitation at extreme risk for surgery.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-01-31

本研究在极手术高危患者中,前瞻性、非随机、单臂评估经导管主动脉瓣置换术对合并重度二尖瓣反流或重度三尖瓣反流的症状性重度主动脉瓣狭窄患者的结局。两组各53例,1年全因死亡或主要卒中分别為21.0%和19.2%,均无主要卒中,结论认为该治疗合理且安全并改善房室瓣反流。

要点

  • 极手术高危合并重度二尖瓣或三尖瓣反流患者行经导管主动脉瓣置换术1年全因死亡或主要卒中分别为21.0%和19.2%。
  • 1年时二尖瓣反流改善者占72.7%,三尖瓣反流改善者占61.8%。
  • 两组1年内均无主要卒中发生。

核心结论

  • 在极手术高危的严重二尖瓣反流或严重三尖瓣反流患者中,经导管主动脉瓣置换术合理且安全,并可改善房室瓣反流。

研究设计与样本

  • 前瞻性、非随机、单臂CoreValve美国扩展使用研究,纳入极手术高危的症状性重度主动脉瓣狭窄合并重度二尖瓣反流或重度三尖瓣反流患者,每组各53例。

主要发现

  • 重度二尖瓣反流组与重度三尖瓣反流组年龄分别为84.2±6.4岁与84.9±6.5岁,男性分别为29例(54.7%)与22例(41.5%),平均胸外科医师协会评分分别为9.9%±5.0%与9.2%±4.0%。
  • 从基线至1年瓣膜反流改善在重度二尖瓣反流组为72.7%,在重度三尖瓣反流组为61.8%。
  • 6个月有利的医疗获益在重度二尖瓣反流组为47例中31例(66.0%),在重度三尖瓣反流组为47例中33例(70.2%)。
  • 1年有利的医疗获益在重度二尖瓣反流组为44例中25例(56.8%),在重度三尖瓣反流组为45例中24例(53.3%)。
  • 30天全因死亡或主要卒中在重度二尖瓣反流组为11.3%,在重度三尖瓣反流组为3.8%;1年分别为21.0%与19.2%,两组1年均无主要卒中。

关键数值与推荐

  • 主要终点为1年全因死亡或主要卒中。
  • 有利的医疗获益定义为6个月堪萨斯城心肌病问卷总体摘要评分大于45且1年大于60,并且较基线下降小于10分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Patients with symptomatic severe aortic stenosis and severe mitral regurgitation or severe tricuspid regurgitation were excluded from the major transcatheter aortic valve replacement trials. We studied these 2 subgroups in patients at extreme risk for surgery in the prospective, nonrandomized, single-arm CoreValve US Expanded Use Study. METHODS: The primary end point was all-cause mortality or major stroke at 1 year. A favorable medical benefit was defined as a Kansas City Cardiomyopathy Questionnaire overall summary score greater than 45 at 6 months and greater than 60 at 1 year and with a less than 10-point decrease from baseline. RESULTS: There were 53 patients in each group. Baseline characteristics for the severe mitral regurgitation and severe tricuspid regurgitation cohorts were age 84.2 ± 6.4 years and 84.9 ± 6.5 years; male, 29 (54.7%) and 22 (41.5%), and mean Society of Thoracic Surgeons score 9.9% ± 5.0% and 9.2% ± 4.0%, respectively. Improvement in valve regurgitation from baseline to 1 year occurred in 72.7% of the patients with severe mitral regurgitation and in 61.8% of patients with severe tricuspid regurgitation. A favorable medical benefit occurred in 31 of 47 patients (66.0%) with severe mitral regurgitation and 33 of 47 patients (70.2%) with severe tricuspid regurgitation at 6 months, and in 25 of 44 patients (56.8%) with severe mitral regurgitation and 24 of 45 patients (53.3%) with severe tricuspid regurgitation at 1 year. All-cause mortality or major stroke for the severe mitral regurgitation and severe tricuspid regurgitation cohorts were 11.3% and 3.8% at 30 days and 21.0% and 19.2% at 1 year, respectively. There were no major strokes in either group at 1 year. CONCLUSIONS: Transcatheter aortic valve replacement in patients with severe mitral regurgitation or severe tricuspid regurgitation is reasonable and safe and leads to improvement in atrioventricular valve regurgitation.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Little SH, Popma JJ, Kleiman NS, et al. Transcatheter aortic valve replacement in patients with severe mitral or tricuspid regurgitation at extreme risk for surgery. J Thorac Cardiovasc Surg. 2018. PMID: 29429630. doi:10.1016/j.jtcvs.2017.11.108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。